Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences chief presents rosy view of growth prospects in podast interview

CEO says company is poised for growth following a two-year worldwide co-marketing and distribution deal with ISS Inc.
scientists in lab
New distribution deal with rival creates new sales opportunities

Richard Schumacher, chief executive of Pressure BioSciences Inc (OTCMKTS:PBIO), a Massachusetts-based life science group which makes laboratory devices, is on the road, touting the expansion of the firm’s business.

The chief of this maker of instruments which utilise pressure to control bio-molecular interactions said his company is poised for growth following a two-year worldwide co-marketing and distribution deal with ISS Inc., an Illinois-based designer of scientific instruments.

Schumacher said on Tuesday in an interview with Uptick Newswires "Stock Day" podcast: “We believe we have set the table to facilitate even greater revenues with the deployment of an experienced, trained, and dedicated field sales team, the acquisition of the BaroFold, Inc. assets – including 8 important patents that integrate well with our own seventeen patents, and our very recently announced co-marketing and distribution relationship with ISS Inc.”

Pressure BioSciences reached the two-year agreement with ISS last month.

One of the products ISS makes is a spectrophotometer -- an instrument used in drug discovery and development -- the pressure for which is usually generated by an “archaic” hand-cranking mechanism.

As its name suggests, Pressure Bio, meanwhile, manufactures automated pressure generators for laboratories which can increase and decrease pressure “like a light switch.”

PBIO’s Hub 440 and the more powerful Hub 880 sell for between US$30,000 and US$50,000 each.

The company doesn’t sell many of these units at the moment, Schumacher said last month, but both parties are expecting to sell more of their respective systems on the back of the tie-up.

In midday trading, shares of the company were flat at US$4.80.

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

1528305384_Untitled-design-(3).jpg
June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
cells
July 31 2018
Life science generally is developing at an incredible speed, says Joe Anderson
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use